“Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases” (2009) Hematology Meeting Reports (formerly Haematologica Reports), 2(6). doi:10.4081/hmr.v2i6.771.